中文摘要：

目的 分析养血清脑颗粒用于慢性脑血管供血不足中的疗效及对患者抑郁、睡眠、血液流变学指标等的影响。方法 选择符合本研究相关标准的慢性脑血管供血不足患者120例纳入研究,按双盲法分为观察组（常规治疗＋养血清脑颗粒治疗）、对照组（常规治疗＋尼莫地平治疗）;使用中医症状积分及临床症状缓解程度评估疗效,记录血液流变学指标变化,比较两组治疗前后中医证候积分、汉密尔顿焦虑量表（Hamilton Anxiety Scale,HAMA）、汉密尔顿抑郁量表（Hamilton Depression Scale,HAMD）、蒙特利尔认知量表（Montreal Cognitive Assessment,Mo CA）、匹兹堡睡眠量表（Pittsburgh sleep quality index,PSQI）、简易精神状态检查量表（mini-mentalstate examination,MMSE）分值;对比两组不良反应的发生率。结果 观察组治疗总有效率（93.33%）较对照组（63.33%）高,差异有统计学意义（P〈0.05）。治疗后观察组纤维蛋白原、血浆比黏度、全血比黏度均较对照组低,差异有统计学意义（P〈0.05）,观察组中医证候积分、HAMA、HAMD、PSQI分值均低于对照组,差异有统计学意义（P〈0.05）。观察组不良反应发生率（3.33%）与对照组（1.67%）比较差异不显著（P〉0.05）。结论 两种药物均有一定疗效,与尼莫地平相比,养血清脑颗粒具有以下明显优势：（1）提高CCCI临床疗效;（2）显著改善患者血液流变学指标,效果更好;（3）能缓解CCCI后抑郁、焦虑情绪,预防抑郁,改善患者睡眠质量。

英文摘要：

Objective To analyze the efficacy of Yangxue Qingnao granules in the treatment of the patients with chronic cerebrovascular insufficiency and its effect on depression, sleep and hemorheology. Methods 120 patients with chronic cerebrovascular insufficiency who met the above criteria were included in the study. They were assigned to the observation group （conventional treatment＋Yangxue Qingnao granules）, and the control group （conventional treatment＋nimodipine） by double-blind method; TCM symptom scores and relief degree of clinical symptoms were used to assess the effi- cacy, and changes in hemorheological indicators were recorded. Scores of TCM symptom scores, Hamilton Anxiety Scale （HAMA）, Hamilton Depression Scale （HAMD）, Montreal Cognitive Assessment （MoCA）, Pittsburgh Sleep Quality Index （PSQI）, mini-mental state examination （MMSE） were compared between the two groups before and after the treatment. The incidence of adverse reactions was compared between the two groups. Results The total effective rate（93.33%） in the observation group was higher than that in the control group （63.33%） （P〈0.05）; after treatment, fibrinogen, plasma specific viscosity and whole blood viscosity in the observation group were lower than in the control group（P〈0.05 for all）; The scores of TCM syndrome, HAMA, HAMD and PSQI scores in the observation group were lower than those in the control group（P〈0.05 for all）. There was no significant difference in the incidence rate of adverse reactions between the observation group（3.33%） and the control group （1.67%） （P〉0.05）. Conclusion Both drugs have certain efficacy. Compared with nimodipine, Yangxue Qingnao granules have the following significant advantages： ① Improving the clinical efficacy of CCCI; ②Significantly improving the hemorheological indicators, with better effect; ③ Alleviating depres- sion and anxiety after CCCI, preventing depression, and improving the quality of sleep.